Suramin (Antrypol)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 02:09, 30 July 2023 by Jwarner (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mechanism of action

Antiparasitic with mechanism of action unclear.

Diseases for which it was used

History of changes in FDA indication

  • This drug is not FDA approved. Of note, it was investigated in prostate cancer but utility was not proven and investigations have been discontinued.

Also known as

  • Brand name: Antrypol
Retrieved from "https://hemonc.org/w/index.php?title=Suramin_(Antrypol)&oldid=75975"